Please assess the completion status of the following clinical trial:

Trial Title: A Study of SC-007 in Subjects With Advanced Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed advanced metastatic or unresectable advanced colorectal cancer (CRC) or gastric cancer that is relapsed, refractory, or progressive after:~* CRC: at least 2 prior systemic regimens in the metastatic setting, and as appropriate in patients whose tumors are microsatellite instability-high (MSI-H), pembrolizumab as well.~* Gastric cancer (including gastric and EGJ cancers): at least 2 prior systemic regimens in adjuvant, advanced, or metastatic setting and, as appropriate, a human epidermal growth factor receptor 2 (HER2) targeted agent.~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* Adequate hematologic, hepatic, and renal function.~Exclusion Criteria:~* Any significant medical condition that, in the opinion of the investigator or sponsor, may place the participant at undue risk from the study.~* Has electrocardiogram (ECG) abnormalities that make QT interval corrected (QTc) evaluation difficult.~* Prior exposure to a pyrrolobenzodiazepine or indolinobenzodiazepine based drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- SC-007 (Type: EXPERIMENTAL): SC-007 intravenous (IV) (various doses and dose regimens)

Based on this trial design, predict the completion outcome and termination type (if applicable).